HIGHLIGHTS
- What: The PILOT study, focusing on patients not eligible for HSCT, showed an ORR of 80% and a CR rate of 48%.18‑20 Despite these promising results, CAR T-cell therapies are associated with significant toxicities, particularly CRS and ICANS.
- Who: Emaan Haque et al. from the Alfaisal University, University of Jordan, Houston Methodist Hospital, Baylor College of Medicine have published the Article: The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma, in the Journal: (JOURNAL) of November/20,/2024
- Future: Future research will . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.